Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.68
+6.26 (2.63%)
AAPL  258.27
+2.86 (1.12%)
AMD  252.03
+0.72 (0.29%)
BAC  52.17
+0.15 (0.29%)
GOOG  335.00
+1.41 (0.42%)
META  672.97
+0.61 (0.09%)
MSFT  480.58
+10.30 (2.19%)
NVDA  188.52
+2.05 (1.10%)
ORCL  174.90
-7.54 (-4.13%)
TSLA  430.90
-4.30 (-0.99%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.